Our study establishes a Tumor Microenvironment-derived Prognostic Model (MPM) that integrates eight TME-associated genes (CXCL12, GZMB, ITPR2, LYN, RAB9B, RGMB, RUFY4, TRIM16) to stratify AML patients into distinct risk categories with significant survival differences. This evidence concerns the gene LYN and acute myeloid leukemia.